Dalbavancin: A novel antimicrobial

A. Y. Chen, M. J. Zervos, J. A. Vazquez

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

The increasing incidence of serious infections because of Gram-positive pathogens and the rising cost in parenteral administration of antimicrobials has inspired the development of a novel antibiotic. Dalbavancin is the first once a week antibiotic with activity against a broad range of Gram-positive pathogens. A large multicentre, pivotal, Phase III clinical trial, which included 854 patients with complicated skin and skin structure infections, compared 1-2 doses of dalbavancin vs. linezolid. The results demonstrated non-inferiority and a comparable safety profile. With its unique pharmacokinetic profile, ease of use and excellent safety profile, dalbavancin should provide a valuable addition to the armamentarium used to treat infections because of Gram-positive cocci.

Original languageEnglish (US)
Pages (from-to)853-863
Number of pages11
JournalInternational Journal of Clinical Practice
Volume61
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Linezolid
Infection
Anti-Bacterial Agents
Safety
Gram-Positive Cocci
Phase III Clinical Trials
Skin
Pharmacokinetics
Costs and Cost Analysis
Incidence
dalbavancin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dalbavancin : A novel antimicrobial. / Chen, A. Y.; Zervos, M. J.; Vazquez, J. A.

In: International Journal of Clinical Practice, Vol. 61, No. 5, 01.05.2007, p. 853-863.

Research output: Contribution to journalReview article

Chen, A. Y. ; Zervos, M. J. ; Vazquez, J. A. / Dalbavancin : A novel antimicrobial. In: International Journal of Clinical Practice. 2007 ; Vol. 61, No. 5. pp. 853-863.
@article{29ee3308c53f48ad96b60354b4aa0cd8,
title = "Dalbavancin: A novel antimicrobial",
abstract = "The increasing incidence of serious infections because of Gram-positive pathogens and the rising cost in parenteral administration of antimicrobials has inspired the development of a novel antibiotic. Dalbavancin is the first once a week antibiotic with activity against a broad range of Gram-positive pathogens. A large multicentre, pivotal, Phase III clinical trial, which included 854 patients with complicated skin and skin structure infections, compared 1-2 doses of dalbavancin vs. linezolid. The results demonstrated non-inferiority and a comparable safety profile. With its unique pharmacokinetic profile, ease of use and excellent safety profile, dalbavancin should provide a valuable addition to the armamentarium used to treat infections because of Gram-positive cocci.",
author = "Chen, {A. Y.} and Zervos, {M. J.} and Vazquez, {J. A.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1111/j.1742-1241.2007.01318.x",
language = "English (US)",
volume = "61",
pages = "853--863",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Dalbavancin

T2 - A novel antimicrobial

AU - Chen, A. Y.

AU - Zervos, M. J.

AU - Vazquez, J. A.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - The increasing incidence of serious infections because of Gram-positive pathogens and the rising cost in parenteral administration of antimicrobials has inspired the development of a novel antibiotic. Dalbavancin is the first once a week antibiotic with activity against a broad range of Gram-positive pathogens. A large multicentre, pivotal, Phase III clinical trial, which included 854 patients with complicated skin and skin structure infections, compared 1-2 doses of dalbavancin vs. linezolid. The results demonstrated non-inferiority and a comparable safety profile. With its unique pharmacokinetic profile, ease of use and excellent safety profile, dalbavancin should provide a valuable addition to the armamentarium used to treat infections because of Gram-positive cocci.

AB - The increasing incidence of serious infections because of Gram-positive pathogens and the rising cost in parenteral administration of antimicrobials has inspired the development of a novel antibiotic. Dalbavancin is the first once a week antibiotic with activity against a broad range of Gram-positive pathogens. A large multicentre, pivotal, Phase III clinical trial, which included 854 patients with complicated skin and skin structure infections, compared 1-2 doses of dalbavancin vs. linezolid. The results demonstrated non-inferiority and a comparable safety profile. With its unique pharmacokinetic profile, ease of use and excellent safety profile, dalbavancin should provide a valuable addition to the armamentarium used to treat infections because of Gram-positive cocci.

UR - http://www.scopus.com/inward/record.url?scp=34247092376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247092376&partnerID=8YFLogxK

U2 - 10.1111/j.1742-1241.2007.01318.x

DO - 10.1111/j.1742-1241.2007.01318.x

M3 - Review article

C2 - 17362476

AN - SCOPUS:34247092376

VL - 61

SP - 853

EP - 863

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 5

ER -